An Open-Label Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (RECAP) | Zendy

Ulrich Costabel | Zendy; Carlo Albera | Zendy; Lisa Lancaster | Zendy; Chin-Yu Lin | Zendy; Philip Hormel | Zendy; Henry N. Hulter | Zendy; Paul W. Noble | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

An Open-Label Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (RECAP)

Author(s) -

Ulrich Costabel,

Carlo Albera,

Lisa Lancaster,

Chin-Yu Lin,

Philip Hormel,

Henry N. Hulter,

Paul W. Noble

Publication year - 2017

Publication title -

respiration

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.264

H-Index - 81

eISSN - 1423-0356

pISSN - 0025-7931

DOI - 10.1159/000479976

Subject(s) - pirfenidone , medicine , idiopathic pulmonary fibrosis , discontinuation , adverse effect , gastroenterology , surgery , lung

RECAP (NCT00662038) was an open-label extension study in patients with idiopathic pulmonary fibrosis (IPF) who completed either the Assessment of Pirfenidone to Confirm Efficacy and Safety in Idiopathic Pulmonary Fibrosis (ASCEND) 016 phase 3 trial or the Clinical Studies Assessing Pirfenidone in Idiopathic Pulmonary Fibrosis: Research of Efficacy and Safety Outcomes (CAPACITY) 004/006 phase 3 trials.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research